Drugs / CV9103
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00906243 | May 2009 → Dec 2010 | hormone-resistant prostate carcinoma | University of Florida | Terminated | No outcome recorded |
| Phase 1/2 | NCT00831467 | Jan → Dec 2009 | hormone-resistant prostate carcinoma | CureVac | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-07-07 | CureVac | Results CureVac veröffentlicht Daten aus seiner klinischen Phase-I/IIa-Studie zur mRNA-basierten Krebsimmuntherapie bei Prosta-takarzinom im Journal for ImmunoTherapy of Cancer curevac.com ↗
Damit werden zum ersten Mal Daten aus einer Phase-IIa-Studie mit einem mRNA-Immuntherapeutikum veröffentlicht, die antigen-spezifische Immunantworten bei der Mehrzahl der Patienten belegen. |
All press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV9103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00906243 ↗ |
| Modality | Messenger RNA (mRNA) | “two-component mRNA-based tumor vaccine” PMID 21150709 ↗ Jan 2011 |
| Route | Other | “CV9103 is applied intradermally” NCT00831467 ↗ |